Cargando…
Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
INTRODUCTION: Heart failure with preserved ejection fraction (HFpEF), which is a common co-morbidity in patients with maintenance hemodialysis (MHD), results in substantial mortality and morbidity. However, there are still no effective therapeutic drugs available for HFpEF currently. Sacubitril/vals...
Autores principales: | Guo, Yanhong, Ren, Mingjing, Wang, Tingting, Wang, Yulin, Pu, Tian, Li, Xiaodan, Yu, Lu, Wang, Liuwei, Liu, Peipei, Tang, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681904/ https://www.ncbi.nlm.nih.gov/pubmed/36440034 http://dx.doi.org/10.3389/fcvm.2022.955780 |
Ejemplares similares
-
Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
por: Zhang, Wenchao, et al.
Publicado: (2021) -
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
por: Schauer, Antje, et al.
Publicado: (2021) -
Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021) -
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023) -
Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)